
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY AND INSTRUMENT COMBINATION TEMPLATE
A. 510(k) Number:
k153278
B. Purpose for Submission:
Modified devices to add compatibility with Android mobile platforms
C. Measurand:
Capillary Whole Blood Glucose from the fingertip palm, forearm, upper arm, calf or thigh
D. Type of Test:
Quantitative, amperometric assay, glucose oxidase
E. Applicant:
Andon Health Co., Ltd
F. Proprietary and Established Names:
iHealth Wireless Smart Gluco-Monitoring System (BG5)
G. Regulatory Information:
Regulation Name Class Product Code Panel
21 § 862.1345 Glucose test system II NBW (75) Chemistry
21 § 862.1345 Glucose Oxidase II CGA (75) Chemistry
21 § 862.2100 Calculator/data processing I JQP (75) Chemistry
module for clinical use
H. Intended Use:
1. Intended use(s):
See indications for use, below.
1

[Table 1 on page 1]
	Regulation			Name			Class			Product Code			Panel	
21 § 862.1345			Glucose test system			II			NBW			(75) Chemistry		
21 § 862.1345			Glucose Oxidase			II			CGA			(75) Chemistry		
21 § 862.2100			Calculator/data processing
module for clinical use			I			JQP			(75) Chemistry		

--- Page 2 ---
2. Indication(s) for use:
The iHealth Wireless Gluco-Monitoring System consists of the iHealth Wireless Glucose
meter (BG5), iHealth Blood Glucose Test Strips (AGS-1000I), and the iHealth Gluco-
Smart App mobile application. The iHealth Wireless Gluco-Monitoring System is
intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary
whole blood samples drawn from the fingertip, palm, forearm, upper arm, calf, or thigh.
The iHealth Wireless Gluco-Monitoring System is intended to be used by a single person
and should not be shared.
The iHealth Wireless Gluco-Monitoring System is intended for self-testing outside the
body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the
effectiveness of diabetes control. The iHealth Wireless Gluco-Monitoring System should
not be used for the diagnosis of or screening of diabetes or for neonatal use. Alternative
site testing should be done only during steady - state times (when glucose is not changing
rapidly).
3. Special conditions for use statement(s):
· Not for use in critically ill patients
· The iHealth system is not intended for use on neonates
· The iHealth system is not intended for use on arterial blood, serum, or plasma
· The following substances at levels greater than normal or therapeutic levels may
cause significant interference (affect the result by greater than 10%), resulting in an
inaccurate result: ascorbic acid, uric acid, acetaminophen, dopamine, L-dopa
· Do not use haemolysis samples, icterus samples, or high lipemia samples.
· Patients undergoing oxygen therapy may show results lower than actual levels.
· AST should be done only during steady state times when glucose levels are not
changing rapidly.
· Do not perform AST if you think your glucose is low, you are unaware that you
might have hypoglycemia, you are testing for hyperglycemia, your AST results do not
match the way you feel, your routine glucose results fluctuate often
· Do not use AST results to calibrate a continuous glucose monitor (CGM)
· Do not use AST results for insulin dosing calculations
· This device is not for use in people who are severely dehydrated, in people who are
severely hypotensive, or people who are in shock, consult your healthcare
professional immediately when this happens.
· Not for use in individuals who are in a hyperglycemic-hyperosmolar state, with or
without ketosis.
· Use only fresh capillary whole blood samples.
· Very low or very high red blood cell count (hematocrit) can lead to incorrect test
results. If you do not know your hematocrit level, please consult your healthcare
provider.
· For over-the-counter use
· Do not perform AST if you think your glucose is low, you are unaware that you
2

--- Page 3 ---
might have hypoglycemia, you are testing for hyperglycemia, your AST results do not
match the way you feel, your routine glucose results fluctuate often
· Do not use AST results to calibrate a continuous glucose monitor (CGM)
· Do not use AST results for insulin dosing calculations
· If you take acetaminophen or acetaminophen containing medications (Tylenol, certain
cold and flu remedies, or certain prescription drugs) higher than the recommended
levels (>5 mg/dL) then you should know that this medication might affect the
reliability of your blood glucose results and you should not use this Blood Glucose
Monitoring System. If you are unsure, than ask your doctor.
· Certain conditions may cause your blood level of uric acid to rise. These conditions
include gout or kidney disease. Uric acid levels in your blood are measured by a
laboratory test that your doctor orders. You should know that if your blood level of
uric acid is high (≥10 mg/dL) then your blood glucose results may be not reliable. If
your doctor tells you that your uric acid level is greater than 10 mg/dL, then do not
use this blood glucose monitoring system. If you are unsure, then ask your doctor.
· Vitamin C (Ascorbic acid (>2 mg/dL) naturally in your blood or from food or taking
Vitamin C supplements might cause inaccurate blood glucose results when using this
blood glucose monitoring system.
4. Special instrument requirements:
iHealth Wireless Smart Glucose Meter (BG5)
I. Device Description:
The iHealth Wireless Smart Gluco-Monitoring System (BG5) consists of the iHealth
Wireless Smart blood glucose meter (BG5), AGS 1000I Test Strips , sterile lancets, lancing
device and the iHealth control solutions. Control solutions provided are for Level I, II, and
III. The iHealth BG5 meter uses Bluetooth 3.0 Wireless radio technology. The iHealth BG5
meter can display the test results and the test results can also be transmitted to an Apple and
Android based mobile device.
iHealth Gluco-Smart App is iOS and Android based software for use with the iHealth BG5
meter. When used with this meter, the iHealth Gluco-Smart App acts as a display and allows
command and control of the meter. The App can transfer data from the device's memory,
manage, and share the data.
Andon is modifying cleared test systems to add Android mobile device compatibility. The
BG5 system has been cleared previously in k150833 with Apple-based hardware and
software. The meter firmware has not changed. The system’s AGS 1000I Test Strips are
identical to the claimed predicate, k123935.
3

--- Page 4 ---
J. Substantial Equivalence Information:
1. Predicate device name(s):
iHealth BG5 Wireless Smart Gluco-Monitoring System
2. Predicate 510(k) number(s):
k123935
3. Comparison with predicate:
Similarities
Predicate Device Candidate Device
iHealth BG5 Wireless Smart iHealth Wireless Smart Gluco-
Item
Gluco-Monitoring System Monitoring System (BG5)
(k123935) (k153278)
IFU Is intended to be used for Same
quantitative measurement
of glucose in fresh
capillary whole blood as an
aid to monitor the
effectiveness of diabetes
control in people with
diabetes.
Sample Source Capillary whole blood from Same
fingertip, palm, forearm,
upper arm, calf or thigh
Model BG5 (Bluetooth) Same
Enzyme Glucose oxidase Same
Measuring range 20 – 600 mg/dL Same
Hematocrit range 20-60% Same
Connectivity to Bluetooth Same
Meter
Test Strip QR code scan Same
Calibration
Dimensions 9 mm × 34.5mm × 19mm Same
Mobile App name iHealth Gluco-Smart App Same
4

[Table 1 on page 4]
		
Similarities		
		
		
	Predicate Device	Candidate Device
	iHealth BG5 Wireless Smart	iHealth Wireless Smart Gluco-
Item		
	Gluco-Monitoring System	Monitoring System (BG5)
		
	(k123935)	(k153278)
		
IFU	Is intended to be used for
quantitative measurement
of glucose in fresh
capillary whole blood as an
aid to monitor the
effectiveness of diabetes
control in people with
diabetes.	Same
Sample Source	Capillary whole blood from
fingertip, palm, forearm,
upper arm, calf or thigh	Same
Model	BG5 (Bluetooth)	Same
Enzyme	Glucose oxidase	Same
Measuring range	20 – 600 mg/dL	Same
Hematocrit range	20-60%	Same
Connectivity to
Meter	Bluetooth	Same
Test Strip
Calibration	QR code scan	Same
Dimensions	9 mm × 34.5mm × 19mm	Same
Mobile App name	iHealth Gluco-Smart App	Same

--- Page 5 ---
Differences
Predicate Device Candidate Device
iHealth BG5 Wireless Smart iHealth Wireless Smart Gluco-
Item
Gluco-Monitoring System Monitoring System (BG5)
(k123935) (k153278)
Mobile App V2.1 V3.4.3
vCeormsiopnat ible OS iOS 5, 6, 7 iOS 7, 8, 9
version Android 4.0, 4.2, 4.4, 5.0
Phone Platform iPhone 5s iPhone 5s
iPhone 5c iPhone 5c
iPhone 5 iPhone 5
iPhone 4S iPhone 4S
iPhone 4 iPhone 4
iPhone 3GS iPhone 3GS
iPod touch (4th generation) iPod touch (4th generation)
iPod touch (5th generation) iPod touch (5th generation)
iPad2 iPad2
iPad3 iPad3
iPad4 iPad4
iPad Mini iPad Mini
iPad Mini 2 iPad Mini 2
iPad Air iPad Air
iPad Air 2 iPad Air 2
Samsung Galaxy S6 Edge
Samsung Galaxy S6
Samsung Galaxy S5
Samsung Galaxy S4
Samsung Galaxy S3
Samsung Galaxy Note3
Samsung Galaxy Note2
HTC One M7
LG Nexus 4
LG Nexus 5
Motorola Nexus 6
Display Connect to Apple Connect to Apple, and Android
platform and LED platforms and LED meter
meter display display
5

[Table 1 on page 5]
		
Differences		
		
		
	Predicate Device	Candidate Device
	iHealth BG5 Wireless Smart	iHealth Wireless Smart Gluco-
Item		
	Gluco-Monitoring System	Monitoring System (BG5)
		
	(k123935)	(k153278)
		
Mobile App	V2.1	V3.4.3
vCeormsiopnat ible OS
version	iOS 5, 6, 7	iOS 7, 8, 9
Android 4.0, 4.2, 4.4, 5.0
Phone Platform	iPhone 5s
iPhone 5c
iPhone 5
iPhone 4S
iPhone 4
iPhone 3GS
iPod touch (4th generation)
iPod touch (5th generation)
iPad2
iPad3
iPad4
iPad Mini
iPad Mini 2
iPad Air
iPad Air 2	iPhone 5s
iPhone 5c
iPhone 5
iPhone 4S
iPhone 4
iPhone 3GS
iPod touch (4th generation)
iPod touch (5th generation)
iPad2
iPad3
iPad4
iPad Mini
iPad Mini 2
iPad Air
iPad Air 2
Samsung Galaxy S6 Edge
Samsung Galaxy S6
Samsung Galaxy S5
Samsung Galaxy S4
Samsung Galaxy S3
Samsung Galaxy Note3
Samsung Galaxy Note2
HTC One M7
LG Nexus 4
LG Nexus 5
Motorola Nexus 6
Display	Connect to Apple
platform and LED
meter display	Connect to Apple, and Android
platforms and LED meter
display

--- Page 6 ---
K. Standard/Guidance Document Referenced (if applicable):
EN 60601-1-2:2007 – Medical electrical equipment, general requirements for basic safety
and essential performance – Collateral standard: Electromagnetic compatibility
L. Test Principle:
The iHealth Wireless Smart Gluco-Monitoring System (BG5) measures glucose
amperometrically. The reaction of glucose oxidase and an electron mediator in the test strip
with glucose in the sample produces an electrical current which is proportional to the amount
of glucose in the sample. The meter measures the current and converts it to the corresponding
glucose concentration, which is displayed by the meter.
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
As established in k110017
b. Linearity/assay reportable range:
As established in k110017
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
As established in k110017, the system is traceable to NIST SRM#917c reference
material and calibrated to be plasma-equivalent.
Test Strip Stability:
The AGS-1000I blood glucose test strips are identical to the test strips in the predicate
device, iHealth BG5 Wireless Smart Gluco-Monitoring System (k123935). Stability
protocols and acceptance criteria were reviewed in k110017 and support the sponsors
claimed shelf life of 24 month shelf-life when stored at 39 to 86°F (4-30°C) with
relative humidity of <80% and a 90 day stability after opening when stored at 39 to
86°F with relative humidity of <80 %.
Control Solution Stability:
The iHealth Glucose Control Solutions Level I, Level II, and Level III were
previously reviewed in k123935. The control solutions have shelf life of 24 months
from the date of manufacture when stored at 39 to 86°F (4-30°C) with relative
humidity of 10-80% and a 90 day stability after opening when stored at 39 to 86ºF.
6

--- Page 7 ---
d. Detection limit:
As established in k110017.
e. Analytical specificity:
As established in k110017.
The sponsor performed interference studies with spiked venous blood samples at
three glucose concentrations (~80, 120, and 350 mg/dL) that were prepared and
divided into a test (dosed) pool and a control pool. The potential interferants (2
levels) were added to the sample and each sample was tested 5 times. The table below
lists all substances tested at concentrations without significant (<10%) interference.
The following limitations for use are included in the labeling for this device:
If you take acetaminophen or acetaminophen containing medications (Tylenol, certain
cold and flu remedies, or certain prescription drugs) higher than the recommended
levels (>5 mg/dL) then you should know that this medication might affect the
reliability of your blood glucose results and you should not use this Blood Glucose
Monitoring System. If you are unsure, than ask your doctor.
7

--- Page 8 ---
Certain conditions may cause your blood level of uric acid to rise. These conditions
include gout or kidney disease. Uric acid levels in your blood are measured by a
laboratory test that your doctor orders. You should know that if your blood level of
uric acid is high (≥10 mg/dL) then your blood glucose results may be not reliable. If
your doctor tells you that your uric acid level is greater than 10 mg/dL, then do not
use this blood glucose monitoring system. If you are unsure, then ask your doctor.
Vitamin C (Ascorbic acid (>2 mg/dL) naturally in your blood or from food or taking
Vitamin C supplements might cause inaccurate blood glucose results when using this
blood glucose monitoring system.
f. Assay cut-off:
Not applicable
2. Comparison studies:
a. Method comparison with predicate device:
As established in k110017
b. Matrix comparison:
Not applicable. Fresh capillary whole blood is the only acceptable matrix.
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable
b. Clinical specificity:
Not applicable
c. Other clinical supportive data (when a. and b. are not applicable):
The sponsor performed a user performance study in k110017 to demonstrate the
accuracy of the system in the hand of the intended users. The results of this testing are
described in k110017.
The performance established in k110017 was confirmed by evaluating forty subjects
using the iHealth BG1 Align blood glucose meter using 40 meters and 40 Android
devices (10 each of three representative models). Each subject obtained his or her
own fingertip capillary sample and performed a blood glucose control test using the
iHealth BG1 Align blood glucose meter. A professional then collected a fingerstick
blood sample to run on a laboratory reference method (YSI 2300).
8

--- Page 9 ---
The results are described below:
User Performance Results comparing meter fingerstick results to YSI
Glucose Concentrations ≤75 mg/dL
Within ±5 mg/dL Within ±10 mg/dL Within ±15 mg/dL
7/10 10/10 10/10
70% 100% 100%
Glucose Concentrations >75 mg/dL
Within ±5 % Within ±10 % Within ±15 % Within ±20%
21/30 29/30 30/30 30/30
70% 97% 100% 100%
The sponsor conducted a linear regression analysis of the data collected for this
confirmatory user performance study. The results are as follows:
Regression Equation R2
y = 1.033x – 1.169 0.9872
Usability Questionnaire: Using representative Android platforms, the 40
participants in the User Performance, who had average computer skills and no prior
knowledge of the system, were assessed to determine if typical users can use the new
device without direct instruction or training. Study results demonstrated that
participants rated the ease of use of the devices as normal or above.
4. Clinical cut-off:
Not applicable
5. Expected values/Reference range:
The sponsor included the following expected values for people without diabetes in the
labeling:
Time of day People without diabetes
Fasting and before meals <100 mg/dL
2 hours after meals <140 mg/dL
Source: American Diabetes Association: Classification and Diagnosis of Diabetes
(Position Statement). Diabetes Care 39 (Supp. 1) S15, 2016.
N. Instrument Name:
iHealth Wireless Smart Gluco-Monitoring System (BG5)
9

[Table 1 on page 9]
Within ±5 mg/dL	Within ±10 mg/dL	Within ±15 mg/dL
7/10	10/10	10/10
70%	100%	100%

[Table 2 on page 9]
Within ±5 %	Within ±10 %	Within ±15 %	Within ±20%
21/30	29/30	30/30	30/30
70%	97%	100%	100%

[Table 3 on page 9]
Regression Equation	R2
y = 1.033x – 1.169	0.9872

[Table 4 on page 9]
Time of day	People without diabetes
Fasting and before meals	<100 mg/dL
2 hours after meals	<140 mg/dL

--- Page 10 ---
O. System Descriptions:
1. Modes of Operation:
Does the applicant’s device contain the ability to transmit data to a computer, webserver,
or mobile device?
Yes ____X____ or No ________
Does the applicant’s device transmit data to a computer, webserver, or mobile device
using wireless transmission?
Yes ___X_____ or No ________
2. Software:
FDA has reviewed applicant’s Hazard Analysis and software development processes for
this line of product types:
Yes ___X_____ or No ________
3. Specimen Identification:
Samples are applied directly to the test strip as they are collected.
4. Specimen Sampling and Handling:
This device is intended to be used with capillary whole blood from AST (Alternative site
testing, including palm, forearm, upper arm, calf, or thigh) and finger.
5. Calibration:
Calibration of the meter occurs by scanning of a 2D barcode (QR Code) located on the
top of the test strip vial by the built in camera of a smartphone that is used in conjunction
with the device. The QR code must be scanned each time a new vial is opened.
6. Quality Control:
The iHealth Control solution are used as a quality control checks to make sure that the
iHealth BG5 Wireless Smart Gluco-Monitoring System and the AGS-1000I blood
glucose test strips are working correctly. The labeling provides instructions on when
quality control testing should be performed.
10

--- Page 11 ---
P. Other Supportive Instrument Performance Characteristics Data Not Covered In
The “Performance Characteristics” Section above:
1. Software: Software documentation was reviewed and demonstrated that the device
was developed under appropriate software lifecycle processes.
2. Electromagnetic compatibility (EMC) (radiated emissions and immunity) testing:
As established in k123935
3. Data transmission accuracy: Bench testing was performed to verify the
transmission accuracy of electrical signals between the glucose meter and the
representative Android devices. This evaluation consisted of the following: sending
of data (output from glucose meter) and receiving of data (input into Android device).
Data from the glucose meter and the receiving data on the Android device was in
100% agreement.
4. Infection Control and Robustness Studies:
iHealth Wireless Smart Gluco-Monitoring System (BG5) is intended for single-
patient use. The sponsor stated that the disinfection efficacy for the meters was
established in k110017 and that the materials comprising the candidate meters are
identical. CaviWipes Disinfecting Towelettes (EPA registration #46781-8) were
previously validated through disinfection efficacy studies demonstrating complete
inactivation of hepatitis B (HBV) virus using materials comprising the meter.
Robustness testing was previously established in k123935, demonstrating that there
was no change in performance or in the external materials of the meter after 11,000
cleaning and disinfection cycles (one cycle includes one cleaning wipe plus one
disinfecting wipe) to simulate 5 years of single-patient use. Labeling was reviewed
for adequate instructions for the validated cleaning and disinfection procedures.
5. Hematocrit: As established in k123935, the claimed hematocrit range is 20-60%
6. Altitude: As established in k123935, the claimed altitude is 10,744 ft.
7. Temperature and Humidity operating conditions: As established in k123935.
Operating temperature is from 10-40ºC with a relative humidity of 10-80%.
8. Sample volume: As established in k110017. The minimum sample volume is 0.7 µL.
9. Readability: A readability assessment was conducted and the results demonstrated
that the User Manual, test strip package insert and control solution package insert
were written at the 8th grade level.
Q. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
11

--- Page 12 ---
R. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.
12